Skip to main content
. 2003 Feb;41(2):867–872. doi: 10.1128/JCM.41.2.867-872.2003

TABLE 1.

Phenotypic and genotypic characterization of the 50 MRSA isolates by different methods

Group and isolate Antibiotic susceptibility toa:
Phage typing result
Pulso- type Mutationc
E T C F R V Tri G Cip Basic international set Experimental sets mecI mec promoter
nmMRSA
    1
        J15 S S S S S S S S S 29/52/52A/80/3A/3C/55/6/42E/47/53/54/75/77/84/95 67R A
        J17 R R S S S S S S S 29/52/52A/80/3A//55/6/42E/47/53/54/75/77/84/81/95 67R A3 6
        J27 S S S S S S S S S 6/42E/47/53/54/83A/85/90 47T/56B/56C/90A/1648/13M/M5/F30/MR12/MR25 B 6
        J28 S S S S S S S S S 29/52/52A/79/80/3A/3C/55/6/42E/47/53/54/75/77/84/81/94/9 56A/87M/MR12 A1 1 6
        J29 S S S S S S S S S 29/52/80/53/77/95/90 47T/MR12 C 6
        J32 S S S S S S S S R 6/42E/47/54/77/84/81 MR12 A
        J38 S S S S S S S S S 29/52/52A/80/3A/3C/6/42E/47/54/95 67R A2 6
        J41 S S S S S S S S S 29/52/42A/80/3A/6/42E/47/53/54/77/95 NTb A4 7, 8
        J61 R R S S S S R S S NT MR12/MR25 D 2
        J70 S S S S S S S S S 29/52/52A/80/3A/6/42E/47/53/54/95 NT A1 2 6
    2
        J40 S S S S S S S S R NT NT R1 7
        J75 S S S S S S S S R NT NT S
        J76 S S S S S S S S R NT NT Q
        J77 S S S S S S S S R NT NT Q
        J78 S S S S S S S S R NT NT Q1
        J79 S S S S S S S S R NT NT Q
        J80 S S S S S S S S R NT NT Q
        J81 S S S S S S S S R NT NT Q2
        J82 S S S S S S S S R NT NT Q
        J83 S S S S S S S S R NT NT Q
        J84 S S S S S S S S R NT NT S
    3
        J33 S S S S S S S S R NT F30 R 3
        J37 R R S S S S S S S 75/84 NT E 6
        J39 S R S R S S S S S NT NT S 6
        J58 R S R S S S S S R NT NT Q
        J59 R S R S S S S S R NT NT Q
        J62 R S R S S S S S S NT NT Q
        J63 R S R S S S S S S NT NT R
        J64 R S R S S S S S S NT NT R
mMRSA
    J1 R R S S S S R R R 84/85/88 47T/56A/87M/622/F38/MR8/MR12/MR25 G 3
    J5 R R S S S S R R R 85/88 47T/622/M5/MR8/MR25 I 3
    J7 R R S S S S R R R 85/88 47T/622/M5/F38/MR8/MR25 G1 3 9
    J12 R S S S S S R R R 84/85/88 47T/87M/622/M5/F38/MR8/MR12/MR25 H
    J13 R R S S S S R R R 6/53/54/75/77/83A/84/85/90/88 47T/56A/56B/56C/1648/67R/87M/622/M3/M5/F33/F38/MR8/MR12/MR25 G2 3, 4
    J18 R R S S S S R R R 29/6/53/54/75/83A/84/85/88 47T/56A/56B/56C/1648/67R/87M/13M/622/M3/M5/F33/F38/MR8/MR12/MR2 G2 3
    J19 R R S S S S R R R 29/85/88 47T/622/M3/M5/F33/F38/MR8/MR12/MR25 H1 3, 4
    J20 R R S S S S R R R 83A/85/88 47T/87M/M5/F38/MR12/MR25 H1 3
    J21 R R S S S S R R R 85/88 47T/56A/622/M5/MR8/MR25 T 3
    J23 R R S S S S R R S 85/88 47T/56A/622/M5/MR8/MR25 F 3
    J24 R R S S S S R R R 83A/85/88 56A/56B/56C/67R/87M/622/F30/F33/F38/MR8/MR12/MR25 F1 3, 4
    J25 R R S S S S R R R 83A/85/88 56A/56B/56C/67R/87M/622/M3/MR8/MR12/MR25 J 3
    J26 R R S S S S R R R NT NT K 5
    J85 R R S S S S R R R 84/85/88 47T/56A/87M/622/M3/M5/F30/F33/F38/MR8/MR12/MR25 H2 3
Archaic
    J42 R R R S S S S S S 6/42E/47/53/54/77/84/85 622/M5/F33/F38/MR25 M
    J44 R R S S S S S S S 79/6/42E/47/53/54/75/77/83A//84/85/81/90 47T/56A/1648/67R/87M/622/M5/F30/F33/F38/MR25 O
    J49 S R S S S S S S S 47/53/75/77/83A/84/85/90 47T/56A/67R/87M/F38 O1
    J50 R R S S S S S S S 75/77/84 NT O1
    J51 R R S S S S S S S 6/42E/47/53/54/77/84/85 622/M5/F33/F38/MR25 N
    J53 R R S S S S S S S 6/42E/47/53/54/77/84/85 622/M5/F33/F38/MR25 P
    J54 R R S S S S S S S 79/6/42E/47/53/54/75/77/83A//84/85/81/90 47T/56A/1648/67R/87M/622/M5/F30/F33/F38/MR25 O3
a

E, erythromycin, T, tetracycline; C, chloramphenicol; E, fusidic acid; R, rifampin; V, vancomycin; Tri, trimethoprim; G, gentamicin; Cip, ciprofloxacin; R, resistant; S, susceptible. All 50 strains were resistant to penicillin and methicillin and sensitive to rifampin and vancomycin.

b

NT, nontypeable.

c

−, mec1 deletion.

d

I, 202C→T; 2, 324T→G; 3, 93A→G; 4, 5-G insertion; 5, 208A→T; 6, G→T mecA SD; 7, A insertion upstream of mecA SD; 8, A deletion at mecA −35; 9, G insertion in mecA SD.